Getting My ABBV-744 BRD4 inhibitor clinical efficacy in refractory cancers To Work
These side effects were being notably milder as compared to an inhibitor of both of those bromodomains. An in depth molecular Evaluation also disclosed that ABBV-744 preferentially inhibits the expression of Androgen Receptor (AR)-dependent genes. ― Stephen Taylor88 These preclinical studies deliver paradigms for future clinical trials in AML,